1026 Bayer AskBio EMB Mon 330a ET
BioCentury & Getty Images


Bayer’s $2B deal for AskBio follows biotech’s decision to bet on its own pipeline

Deal gives Bayer gene therapy programs, manufacturing and technologies

The deal gives Bayer clinical and preclinical gene therapy programs, manufacturing capabilities and platform technologies.

Oct 26, 2020 | 11:55 AM GMT

Gene therapy company AskBio chose last year to raise VC cash and invest in its pipeline rather than continue to rely solely on licensing and transaction revenues that had kept it afloat since 2001. That decision primed the biotech for its takeout by Bayer on Monday

Read the full 987 word article

How to gain access

Continue reading with a
two-week free trial.